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Abstract
Sex differences are known to exist in adipose and immune functions in the body, and sex steroid hormones are
known to be involved in sexually dimorphic biological and pathological processes related to adipose-immune
interaction. However, our knowledge of proteins that mediate such differences is poor. Two novel obese mice
models, Mito-Ob and m-Mito-Ob, that have been reported recently have revealed an unexpected role of a
pleiotropic protein, prohibitin (PHB), in sex differences in adipose and immune functions. This discovery points
towards a role of pleiotropic proteins and their potential interplay with sex steroid hormones in mediating sexually
dimorphic adipose-immune interaction.
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Mitochondrial functions encompass the anaplerotic tri-
carboxylic acid cycle and energy production, but these
functions are often finely tuned to serve specific roles in
different cell types or tissues. Examples are lipogenesis
in white adipocytes, thermogenesis in brown adipocytes,
insulin secretion from pancreatic β cells, and cytokine
production from immune cells. Thus, mitochondrial
proteins involved in fundamental aspects of mitochon-
drial biology are uniquely placed to perform pleiotropic
functions and provide an opportunity to simultaneously
manipulate two different functions in two different cell
types or tissues. However, to the best of our knowledge,
a potential use of such pleiotropic protein in manipulat-
ing two different functions in two different cell types
have not been discussed earlier.
It has been more than 25 years since McClung et al. [1]
have discovered prohibitin (PHB, also known as PHB1) as
an anti-proliferative gene. Up till now, the mechanism of
anti-proliferative function of PHB remains controversial.
Meanwhile, genetic studies with different model organ-
isms have provided evidence for an important role of PHB
as a scaffolding protein in mitochondrial biology [2], and
emerging evidence suggests that PHB has a role in adipo-
genesis [3–5]. Furthermore, PHB has been reported to
function as an adaptor protein in membrane-associated
cell signaling functions in various cell types, including im-
mune cells [6–8]. The plasma membrane-associated cell
signaling function of PHB requires phosphorylation of
PHB at different residues [6, 8]. One of them is tyrosine-
114 in PHB protein [6]. However, it remains unclear
whether mitochondrial and cell signaling functions are in-
terrelated or independent from each other.
Recently, Ande et al. [9–11] have capitalized on the
pleiotropic attribute of PHB to simultaneously manipulate
adipocyte and immune cell-specific functions of PHB in
transgenic mice models, Mito-Ob and m-Mito-Ob. This
was achieved by expressing PHB (Mito-Ob) and m-PHB
(m-Mito-Ob), a phosphomutant form of PHB lacking
tyrosine-114 phosphorylation site, from the aP2 gene
promoter [10, 11]. Because the aP2 gene is known to
primarily expressed in adipocytes but also expressed
in monocytic macrophages and dendritic cells among
various immune cell types (e.g., T and B cells, NK
cells, mast cells, plasma cells, neutrophils, basophils,
and eosinophils) [12–14]. Overexpression of PHB in
adipocytes was found to induce mitochondrial biogen-
esis, adipocyte hypertrophy, and increase in adipose
tissue mass in both female and male transgenic mice
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compared with their age- and sex-matched wild-type
littermates [10]. A similar effect of m-PHB on adipocytes
was found in m-Mito-Ob mice suggesting that phosphoryl-
ation of tyrosine-114 is not required for mitochondria-
related adipogenic function of PHB [11]. Of note, Mito-Ob
and m-Mito-Ob mice were found to gain weight after pu-
berty. Interestingly, the metabolic phenotype of Mito-Ob
and m-Mito-Ob mice revealed a sex dimorphic role of
PHB in adipocyte and immune cell functions as only male
Mito-Ob/m-Mito-Ob mice developed obesity-associated
adipose inflammation, impaired glucose homeostasis, and
insulin resistance [9–11]. With aging, a sex-specific meta-
bolic dysregulation in male Mito-Ob mice led to the devel-
opment of nonalcoholic steatohepatitis (NASH) and
hepatocellular carcinoma (HCC), suggesting sex differences
in adipose-hepatic crosstalk in Mito-Ob mice [15]. Intri-
guingly, metabolic dysregulation in male m-Mito-Ob mice
led to sinus histiocytosis with massive lymphadenopathy
(SHML), revealing an anti-proliferative role of tyrosine-114
in monocytic macrophages and dendritic cells. Female
Mito-Ob and m-Mito-Ob remained protected from HCC
and SHML, respectively, despite comparable obesity with
their male counterparts [10, 11, 15]. Intriguingly, on a high-
fat diet, male m-Mito-Ob mice develop adult-onset type 1
diabetes instead of tumors [16]. The development of HCC
and SHML or autoimmune diabetes in a male sex-specific
manner suggests a sex dimorphic effect of PHB on adipo-
cyte, monocytic macrophage, and dendritic cell functions,
which were not suspected before [17].
Similar to Mito-Ob and m-Mito-Ob mice, an increase
in body weight after puberty has been observed in the
female heterozygous Phb2 knockout mice [18]. In this
context, it is important to note that PHB and its hom-
ologous protein PHB2 heterodimerizes in the inner
mitochondrial membrane and play a role in the main-
tenance of mitochondrial structure and functions [2]. In
addition, PHB2 also functions as a repressor for estrogen
activity [19]. Moreover, PHB has been identified as a tar-
get gene for estrogen [20]. These evidences suggest that
the relationship between PHB and estrogen is complex
and both may regulate each other’s function in the regu-
lation of adipose tissue homeostasis [17].
HCC is sexually dimorphic in humans and rodents
with higher prevalence in males, an effect that depends
on sex steroids [21, 22]. The molecular mechanisms by
which estrogens prevent and androgens promote liver
cancer remain unclear. The focus has been on direct ef-
fect of sex steroids on hepatocytes; however, a potential
role of other cell or tissue type is not explored. Recently,
Foxa1/2 has been shown to play an important role in
sexual dimorphism of HCC as revealed by reversal of
sexually dimorphic HCC in Foxa1/2-deficient mice after
DEN-induced hepatocarcinogenesis [21]. At the same
time, the authors also noticed that without carcinogen
treatment, Foxa1/2 mutant mice maintain much of the
sexual dimorphism gene expression profile that is
present in control livers [21]. This suggests that the loss
of gender specificity in Foxa1/2-deficient mice occurs
with the onset of carcinogen exposures. Given the fact
that multiple physiological and pathophysiological pro-
cesses are sexually dimorphic in the organs expressing
Foxa1/2 proteins, it is likely that other stresses, like in-
flammatory changes, might also invoke gender-specific
responses. Similarly, sex differences in HCC develop-
ment in estrogen and androgen receptor knockout ani-
mals, although diminished, were not entirely abolished
[23, 24]. Collectively, these findings suggest that factors
other than sex steroids and tissues other than hepatic
tissue also contribute to sex differences in the develop-
ment of HCC [15, 17]. The Mito-Ob mice provide evi-
dence that dysregulation of sex differences in adipocytes
and immune cells can cause sex differences in HCC inci-
dence. This makes sense because adipose, immune, and
liver functions are intimately linked in systemic meta-
bolic regulation, and their dysregulation is linked to a
number of diseases. Of note, sex difference in HCC inci-
dence in Mito-Ob mice is further extended to sex-
specific HCC development in male and full protection in
female. In this context, it is important to note that liver-
specific PHB knockout mice have been reported earlier,
which also develop HCC. In PHB knockout mice, out of
38 % (5/13 mice) mice that develop tumors between ages
of 35 and 46 weeks, most were females (4/8 in females
and 1/5 in males) [25]. This would imply that in PHB
knockout mice, sex dimorphism in HCC occurrence is
reversed with increased susceptibility in females com-
pared to male counterpart. Taken together, these find-
ings suggest that PHB overexpression further polarizes
sex differences while its knockdown reverses the effect
on sex differences in adipose, immune, and hepatic func-
tions. Collectively, these evidences suggest that PHB has
an important role in mediating sex differences in a num-
ber of cell or tissue types. Whether PHB mediates such
effects as a downstream target of sex steroids or inde-
pendent of sex steroids remains to be determined, which
warrants further investigation. The development of
SHML in the ovariectomized female m-Mito-Ob mice
suggests a role of sex steroid in the modulation of PHB
function in adipocyte and immune cell functions [11].
In summary, the discovery of PHB in mediating sex
differences and adipose and immune functions and con-
sequently in adipose-immune interaction raises import-
ant questions related to the role of PHB in the biology
of sex differences such as the following:
1. What is the mechanism of PHB-induced sex
differences in adipocyte and immune cell
functions?
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2. Does PHB mediate sex-specific functions?
3. What is relationship between PHB and sex steroids
in mediating sex dimorphic functions?
It is anticipated that a better understanding of the role
of PHB in sexually dimorphic functions in the body may
lead to the discovery of novel ways to modulate adipose
and immune functions and contribute to the development
of more effective, gender-responsive, and personalized
medicine.
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